Despite first director decisions, Arthrex reviews remain clouded in uncertainty
The jury is still out on whether the interim USPTO measures represent a meaningful process or a rubber stamping exercise, while some worry the agency’s acting head Drew Hirshfeld lacks standing to issue them
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.